Heather Bresch will face the proverbial lash from Congress on Wednesday over the escalating cost of Mylan NV’s EpiPen. Her boss won’t.
Robert J. Coury acquired the rights to sell the emergency allergy antidote in 2007 when he was Mylan’s chief executive officer. At the time, the EpiPen cost about $50 a shot. When Coury stepped down as CEO and became the company’s executive chairman in 2011, the price was about $90, according to SSR Health. Now, it’s sold in a two-pack for $600 and, thanks to federal legislation, it’s required in many schools.
